Hyris
Following the first official announcement at the beginning of December last year, Hyris completed the transfer of its shares into Ulisse Biomed via a reverse take-over transaction. The new group, strong of flawless interoperability between its leading technologies, aims to become a new benchmark of innovation in the national and international biotech market.
LONDON, ENGLAND / ACCESSWIRE / January 15, 2024 / A new international biotech group was born from the integration of Hyris Ltd, an innovative biotech company renowned worldwide for its disruptive genetic testing platform, and Ulisse Biomed S.p.A., also known as UBM Group or "UBM" only, an Italian-based publicly traded biotech company appreciated for its innovative testing platforms.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.A new benchmark in the biotech market
As anticipated on December 4th, the integration between Hyris and Ulisse Biomed was officially ratified on December 21st by completing a reverse take-over operation and following the shareholders' meeting of Ulisse Biomed held earlier on that same day, which also deliberated an increase of capital in option. The overarching goal is to give life to a new Italian segment of excellence in genetic analysis based on strong innovation competencies and ready to address international markets at scale.
The new Group, with strong roots in diagnostics, teranosis and healthcare, aims to create a strong actor operating as a leader in the in-vitro diagnostics industry, particularly molecular biology, thanks to flawless interoperability between its leading technologies.
Matteo Petti, CEO of Ulisse Biomed, who will keep his role of managing director in the new corporate structure, is very positive about the whole operation, highlighting how its implications go way beyond a mere financial transaction: "We are excited to announce the integration with Hyris. By joining forces, we will enhance our product offering, combining our experience and development capabilities with Hyris' unique mix of competencies. This integration aims to capitalise on the synergies between the two companies, maximising value for our shareholders and offering unprecedented integrated diagnostic solutions to our customers." He concludes: "The success of this operation projects us towards new horizons, and the joint management will work immediately to leverage the new strategic synergies."
The new structure aims to provide an integrated array of high-end performance products at a competitive cost to meet a diverse industry demand across various markets, defining a new portfolio of distinctive analytical capabilities at a global level.
Stefano Lo Priore, founder of Hyris and former CEO and recently appointed Chairman of UBM Group, agrees: "We are proud of this integration between Ulisse Biomed and Hyris. We have a joint industrial project with a strong vision and have already received excellent feedback from the market regarding the joint proposition of our solutions. As a united company, we will be able to implement the project in a synergic manner and create a unique and distinctive offer on the global and, even more so, on the Italian biotech scene." Priore is confident about the positive outcome of this operation: "Hyris and Ulisse Biomed are now officially part of the same team, united by common values and vision and a unique industrial. We are ready for the challenges that await us, strong of the competencies that the two companies will be able to pool together."
In the next months, the new management will put into action a strategic plan to accelerate team and resource integration, leveraging the two companies' similar cultures and shared values.
For more information, feel free to write an email to info@hyris.net
Contact Information
Gabriele Salaris
Global Experience Manager
gabriele.salaris@hyris.net
+39 345 555 3379
SOURCE: Hyris
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GoodData Announces Launch of MCP Server to Let AI Execute Analytics End-to-End21.1.2026 10:00:00 CET | Press release
Combining MCP, analytics-as-code, and LLMs to automate analytics execution at software speed SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 21, 2026 / GoodData, a leader in AI analytics and decision intelligence, today announced the public launch of its MCP Server. As organisations adopt AI in analytics, most tools remain limited to query generation, leaving teams to manually manage metrics, dashboards and business logic. MCP Server moves AI beyond analysis, enabling governed, end-to-end analytics execution and delivering 10-50x faster time to value. The MCP Server is designed for AI developers, and BI and data teams who want to build and manage analytics faster with AI. It allows AI to build and operate analytics in the same way a skilled human team would, but faster and without operational bottlenecks. Using the Model Context Protocol (MCP), AI agents and large language models (LLMs) can connect directly to GoodData and execute analytics across the full lifecycle. They can wor
Kontent.ai Launches AI-Powered SEO and GEO Workflows to Cut Optimization Time by Up to 80% and Optimize Content for Search and Answer Visibility21.1.2026 08:00:00 CET | Press release
Kontent.ai today announced the launch of new agentic SEO and Generative Engine Optimization (GEO) workflows following early results that show organizations reducing the time required to audit and optimize content performance by up to 80 percent while improving organic and answer engine reach without additional media spend. BRNO, CZ / ACCESS Newswire / January 21, 2026 / As content inventories grow into hundreds of thousands of items, search engine optimization (SEO) has become a significant operational cost. Manual audits, spreadsheet-driven updates, and disconnected tooling make it difficult for teams to keep content accurate, structured, and discoverable across both traditional search engines and AI-driven discovery platforms. Kontent.ai's new agentic workflows are designed to change that cost and effort curve. Embedded directly within the CMS, autonomous agents continuously analyze content for missing or inconsistent metadata, unclear structure, outdated terminology, and weak intern
GA-ASI and Calidus Sign MOU To Collaborate on Co-Production of MQ-9B and Gambit Collaborative Combat Aircraft20.1.2026 18:00:00 CET | Press release
ABU DHABI, UAE / ACCESS Newswire / January 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in unmanned aircraft systems, and Calidus Aerospace, one of the leading defense and manufacturing companies, have signed a Memorandum of Understanding (MOU) to collaborate on the prospective co-production of MQ-9B Remotely Piloted Aircraft and Gambit Collaborative Combat Aircraft (CCA) in the UAE, as well as command and control and battle management systems. The agreement was signed by GA-ASI President David R. Alexander and Dr. Khalifa Murad Alblooshi, Managing Director and CEO of Calidus Holding Group, on the sidelines of the UMEX and SimTEX 2026 taking place January 20-22, 2026. The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Calidus where all parties will look to collaborate on programs in the areas of airframe manufacturing, final assembly, test and checkout, as well as flight operational test and acceptance. "Working with pa
Vossen Capital Management Secures £200 Million in Pre-IPO Investment Commitments20.1.2026 15:20:00 CET | Press release
Vossen Capital Management Ltd ("Vossen Capital" or the "Company"), a specialist investment firm focused on fixed income and private market opportunities, announces that it has secured £200 million in committed capital for its Pre-IPO Investment Programme. LONDON, UK / ACCESS Newswire / January 20, 2026 / Highlights: £200 million committed to Pre-IPO allocations across technology, healthcare, and sustainable infrastructure sectors Expanded institutional partner network providing enhanced deal flow access Strong investor demand driven by track record of successful Pre-IPO placements Programme offers qualified investors early-stage exposure to growth companies ahead of public listings The capital commitments have been secured from a combination of institutional investors, family offices, and high-net-worth individuals seeking exposure to private market opportunities typically reserved for venture capital and institutional funds. Jack Vossen, Head of Private Equity at Vossen Capital, comme
Innodata Awarded Prime Contract Position on U.S. Missile Defense Agency's IDIQ SHIELD Program20.1.2026 14:30:00 CET | Press release
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it was awarded a contract for the Missile Defense Agency Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract. The SHIELD program is designed to drive rapid innovation and deliver next-generation capabilities that strengthen the nation's multi-layered homeland defense architecture. As part of the broader Golden Dome strategy, this selection positions Innodata to compete for future task orders across research, development, engineering, prototyping, and operations of critical Missile Defense Agency systems that support U.S. national security objectives. The award was made as part of a list of companies eligible to compete under the program publicly announced by the U.S. Government on 15-Jan-26. "We are proud to support our nation's mission to defend the homeland," said Vinay Malkani, SVP Federal of Innodata. "This co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
